Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus

Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus

Author Novak, Glaucia V. Google Scholar
Marques, Mariana Google Scholar
Balbi, Verena Google Scholar
Gormezano, Natali W. S. Google Scholar
Kozu, Katia Google Scholar
Sakamoto, Ana P. Autor UNIFESP Google Scholar
Pereira, Rosa M. R. Google Scholar
Terreri, Maria T. Autor UNIFESP Google Scholar
Magalhaes, Claudia S. Google Scholar
Guariento, Andressa Google Scholar
Sallum, Adriana M. E. Google Scholar
Marini, Roberto Google Scholar
Leme Ferriani, Virginia Paes Google Scholar
Barbosa, Cassia Maria Google Scholar
Monteiro de Castro, Tania Caroline Google Scholar
Ramos, Valeria C. Google Scholar
Bonfa, Eloisa Google Scholar
Silva, Clovis A. Google Scholar
Abstract Background: To our knowledge there are no studies assessing anti-Ro/SSA and anti-La/SSB autoantibodies in a large population of childhood-systemic lupus erythematosus (cSLE) patients. Methods: This was a retrospective multicenter cohort study performed in 10 Pediatric Rheumatology services, Sao Paulo state, Brazil. Anti-Ro/SSA and anti-La/SSB antibodies were measured by enzyme linked immunosorbent assay (ELISA) in 645 cSLE patients. Results: Anti-Ro/SSA and anti-La/SSB antibodies were evidenced in 209/645 (32%) and 102/645 (16%) of cSLE patients, respectively. Analysis of cSLE patients with and without anti-Ro/SSA antibodies revealed higher frequencies of malar rash (79% vs. 71%, p = 0.032), photosensitivity (73% vs. 65%, p = 0.035), cutaneous vasculitis (43% vs. 35%, p = 0.046) and musculoskeletal involvement (82% vs. 75%, p = 0.046) in spite of long and comparable disease duration in both groups (4.25 vs. 4.58 years, p = 0.973). Secondary Sjogren syndrome was observed in only five patients with this antibody (2.5% vs. 0%, p = 0.0035), two of them with concomitant anti-La/SSB. The presence of associated autoantibodies: anti-Sm (50% vs. 30%, p < 0.0001), anti-RNP (39% vs. 21%, p < 0.0001) and anti-ribossomal P protein (46% vs. 21%, p = 0.002) was also significantly higher in patients with anti-Ro/SAA antibodies. Further evaluation of cSLE patients with the presence of anti-La/SSB antibodies compared to those without these autoantibodies showed that the frequency of alopecia (70% vs. 51%, p = 0.0005), anti-Sm (59% vs. 31%, p < 0.0001) and anti-RNP (42% vs. 23%, p < 0.0001) were significantly higher in the former group. Conclusions: Our large multicenter cohort study provided novel evidence in cSLE that anti-Ro/SSA and/or anti-La/SSB antibodies were associated with mild manifestations, particularly cutaneous and musculoskeletal. Secondary Sjogren syndrome was rarely observed in these patients, in spite of comparable frequencies of anti-Ro/SSA and/or anti-La/SSB reported for adult SLE. (C) 2016 Elsevier B.V. All rights reserved.
Keywords Anti-Ro/SSA autoantibodies
Anti-La/SSB autoantibodies
Sjogren syndrome and childhood-systemic
lupus erythematosus
Multicenter cohort
xmlui.dri2xhtml.METS-1.0.item-coverage Amsterdam
Language English
Sponsor Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
Federico Foundation
Nucleo de Apoio a Pesquisa "Sande da Crianca e do Adolescente" da USP (NAP-CriAd)
Grant number CNPq: 301805/2013-0
CNPq: 303752/2015-7
CNPq: 301479/2015-1
CNPQ: 305068/2014-8
CNPQ: 303422/2015-7
Date 2017
Published in Autoimmunity Reviews. Amsterdam, v. 16, n. 2, p. 132-135, 2017.
ISSN 1568-9972 (Sherpa/Romeo, impact factor)
Publisher Elsevier Science Bv
Extent 132-135
Access rights Closed access
Type Article
Web of Science ID WOS:000394079900004

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account